Key result
The POLARx cryoballoon demonstrated similar acute pulmonary vein isolation efficacy compared to the AFA-Pro cryoballoon (OR 0.43; 95% CI 0.06-3.03; p=0.40).
Why the study?
A novel cryoballoon system (POLARx) with a more compliant design became available, prompting comparison with the Arctic Front Advance Pro (AFA-Pro) system for procedural efficacy, biophysical parameters, and safety.
Does the POLARx cryoballoon system improve procedural efficacy or safety compared to the AFA-Pro system in patients with atrial fibrillation undergoing pulmonary vein isolation?
Population
310 patients undergoing PVI for AF across 4 studies
Comparison
POLARx vs Arctic Front Advance Pro (AFA-Pro)
Design
Systematic review and meta-analysis
Authors
Loading...
POLARx achieves comparable acute PVI to AFA-Pro; confirms procedural equivalence for AF ablation.
Meta-Analysis (n=310)
Does the POLARx cryoballoon system improve procedural efficacy or safety compared to the AFA-Pro system in patients with atrial fibrillation undergoing pulmonary vein isolation?
Odds Ratio: 0.43 (95% CI 0.06–3.03)
p-value: p=.40
The novel POLARx cryoballoon system demonstrates similar procedural efficacy and safety (phrenic nerve palsy risk) compared to the established AFA-Pro system for pulmonary vein isolation, despite achieving lower nadir temperatures.
Assaf et al. (2021) conducted a meta-analysis in Atrial fibrillation (n=310). POLARx cryoballoon vs. Arctic Front Advance Pro (AFA-Pro) cryoballoon was evaluated on Acute pulmonary vein isolation (PVI) (OR 0.43, 95% CI 0.06 to 3.03, p=.40). The POLARx cryoballoon demonstrated similar acute pulmonary vein isolation efficacy compared to the AFA-Pro cryoballoon (OR 0.43; 95% CI 0.06-3.03; p=0.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: